lh-20220714July 14, 20220000920148false00009201482022-07-142022-07-14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
July 14, 2022
(Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
(Exact Name of Registrant as Specified in its Charter)
| | | | | | | | | | | | | | |
Delaware | | 1-11353 | | 13-3757370 |
(State or other jurisdiction of Incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| | | | | | | | | | | |
358 South Main Street | | |
Burlington, | North Carolina | | 27215 |
(Address of principal executive offices) | | (Zip Code) |
(Registrant’s telephone number including area code) 336-229-1127
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | | | |
☐ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act.
Title of Each Class Trading Symbol Name of exchange on which registered
Common Stock , $0.10 par value LH New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| | | | | |
Item 7.01 | Regulation FD Disclosure
|
On July 14, 2022, Laboratory Corporation of America Holdings (Labcorp) announced that its Board of Directors (the Board) has declared a cash dividend in the amount of $0.72 per share of common stock, to be paid on September 9, 2022 to the holders of record of all of the issued and outstanding shares of common stock as of the close of business on August 18, 2022. A copy of the press release announcing the dividend is furnished as Exhibit 99.1 hereto and incorporated by reference herein.
| | | | | | | | |
Item 9.01 | Financial Statements and Exhibits.
|
| |
Exhibit | Exhibit Name |
Exhibit 99.1 | |
Exhibit 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
| | | | | | | | |
|
| | |
| By: | /s/ SANDRA VAN DER VAART |
| | Sandra van der Vaart |
| | Executive Vice President, Chief Legal Officer and Corporate Secretary
|
July 14, 2022
Document
FOR IMMEDIATE RELEASE
Labcorp Contacts:
Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com
Media: Christopher Allman-Bradshaw – 336-436-8263
Media@Labcorp.com
LABCORP DECLARES QUARTERLY DIVIDEND
BURLINGTON, N.C., July 14, 2022 — Labcorp (NYSE: LH) (the Company), a leading global life sciences company, announced today that its Board of Directors (the Board) has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 9, 2022, to stockholders of record as of the close of business on August 18, 2022.
About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about Labcorp at www.Labcorp.com, or follow us on LinkedIn and Twitter @Labcorp.